Atwood et al. reported that atypical protein kinase Ci/λ (aPKC-i/λ) is a novel GLI1 target gene product, and a novel therapeutic target for SMO inhibitor-resistant BCC [142]. The gene discussed is SMO; the disease is skin basal cell carcinoma.